One day after Roche said it was starting to establish Vabysmo as the new standard of care in age-related macular degeneration (AMD) and diabetic macular edema (DME), Regeneron clapped back with the ...

As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in decline. | As regulatory delays continue to plague Regeneron's Eylea ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The sBLA includes results from the Phase 3 PANORAMA trial, which enrolled 402 patients with NPDR. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

Kodiak Sciences has bounced back from the failure of its eye disease drug candidate, noting that it has matched Regeneron and Bayer’s blockbuster Eylea in a phase 3 trial of macular edema due to ...

The standing of Eylea (aflibercept), which has monopolized the macular degeneration drug market for more than 10 years, is wobbling. As biosimilars enter the market in earnest and next-generation new ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

Shares of Regeneron Pharmaceuticals, Inc. REGN declined 1.13% after the company reported disappointing fourth-quarter preliminary sales for lead drug, Eylea. Sales of Eylea (aflibercept) and Eylea HD ...

Regeneron Pharmaceuticals Inc. ( REGN) announced at the global healthcare conference of JPMorgan ( JPM) that its eye drug Eylea is off to a strong start in the US. Regeneron announced at the ...